Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $46.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price increased by Wells Fargo & Company from $45.00 to $46.00 in a research note released on Thursday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

RARE has been the subject of several other reports. Guggenheim reduced their target price on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a research report on Tuesday, August 4th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Ultragenyx Pharmaceutical in a report on Monday, August 10th. Cantor Fitzgerald increased their price objective on shares of Ultragenyx Pharmaceutical from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday. Royal Bank Of Canada raised their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Finally, Wedbush decreased their target price on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $58.89.

Ultragenyx Pharmaceutical Trading Up 2.0%

Shares of RARE stock opened at $25.83 on Thursday. The stock has a 50 day moving average of $28.58 and a two-hundred day moving average of $24.98. Ultragenyx Pharmaceutical has a 12 month low of $18.29 and a 12 month high of $39.89. The company has a market capitalization of $2.55 billion, a P/E ratio of -4.42 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.32. The company had revenue of $214.00 million for the quarter, compared to analyst estimates of $183.08 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.Ultragenyx Pharmaceutical’s revenue for the quarter was up 28.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.17) EPS. Sell-side analysts predict that Ultragenyx Pharmaceutical will post -4.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 15th. The stock was sold at an average price of $25.05, for a total transaction of $50,100.00. Following the completion of the transaction, the director directly owned 21,095 shares of the company’s stock, valued at approximately $528,429.75. This trade represents a 8.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Karah Herdman Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 15th. The shares were sold at an average price of $24.62, for a total value of $46,753.38. Following the transaction, the executive vice president directly owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. The trade was a 1.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 8,552 shares of company stock worth $207,455 over the last three months. 5.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 14.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock worth $8,414,000 after buying an additional 29,984 shares in the last quarter. Creative Planning acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth approximately $454,000. American Century Companies Inc. acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth approximately $366,000. M&T Bank Corp boosted its holdings in shares of Ultragenyx Pharmaceutical by 19.7% in the 2nd quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock worth $263,000 after acquiring an additional 1,192 shares in the last quarter. Finally, Amundi grew its position in Ultragenyx Pharmaceutical by 1,560.4% during the 2nd quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock worth $3,913,000 after acquiring an additional 93,189 shares during the last quarter. 97.67% of the stock is owned by institutional investors.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: The FDA granted accelerated approval to Genglycos (pariglasgene brecaparvovec), Ultragenyx’s gene therapy for glycogen storage disease type Ia (GSDIa). It is the first FDA-approved treatment designed to address the underlying cause of the rare metabolic disorder, potentially expanding the company’s commercial opportunity and strengthening its gene-therapy platform. Ultragenyx Announces FDA Approval of Genglycos
• Positive Sentiment: Analysts raised their valuations following the approval. Cantor Fitzgerald increased its price target to $103 from $96 and maintained an “overweight” rating; Canaccord raised its target to $83 from $81 with a “buy” rating; Morgan Stanley lifted its target to $74 from $67 and maintained “overweight”; Citi raised its target to $58 from $45 with a “buy” rating; and Wells Fargo increased its target to $46 from $45 while retaining “overweight.” Ultragenyx FDA approval coverage
• Positive Sentiment: Wells Fargo described the gene-therapy launch as a potential long-term revenue tailwind, suggesting Genglycos could create a more durable growth stream for RARE if adoption and reimbursement develop as expected. Wells Fargo Genglycos analysis
• Neutral Sentiment: Despite the regulatory progress, investors still need evidence that Ultragenyx can convert approval into sustainable profitability. The company remains loss-making, making the pace of commercialization, revenue growth and cash generation important tests for the stock. Ultragenyx profitability analysis

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.